1045 例印度 HIV-1 亚型 C 序列中的共受体嗜性预测：对印度的治疗意义。

Co-receptor tropism prediction among 1045 Indian HIV-1 subtype C sequences: Therapeutic implications for India.

机构信息

Department of Pediatrics, St, John's Medical College and Hospital, St, John's National Academy of Health Sciences, Sarjapur Road, Bangalore-560034, India.

出版信息

AIDS Res Ther. 2010 Jul 21;7:24. doi: 10.1186/1742-6405-7-24.

DOI:10.1186/1742-6405-7-24

PMID:20646329

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2918521/

Abstract

BACKGROUND

Understanding co-receptor tropism of HIV-1 strains circulating in India will provide key analytical leverage for assessing the potential usefulness of newer antiretroviral drugs such as chemokine co-receptor antagonists among Indian HIV-infected populations. The objective of this study was to determine using in silico methods, HIV-1 tropism among a large number of Indian isolates both from primary clinical isolates as well as from database-derived sequences.

RESULTS

R5-tropism was seen in 96.8% of a total of 1045 HIV-1 subtype C Indian sequences. Co-receptor prediction of 15 primary clinical isolates detected two X4-tropic strains using the C-PSSM matrix. R5-tropic HIV-1 subtype C V3 sequences were conserved to a greater extent than X4-tropic strains. X4-tropic strains were obtained from subjects who had a significantly longer time since HIV diagnosis (96.5 months) compared to R5-tropic strains (20.5 months).

CONCLUSIONS

High prevalence of R5 tropism and greater homogeneity of the V3 sequence among HIV-1 subtype C strains in India suggests the potential benefit of CCR5 antagonists as a therapeutic option in India.

摘要

背景

了解在印度流行的 HIV-1 毒株的辅助受体嗜性，将为评估新型抗逆转录病毒药物（如趋化因子辅助受体拮抗剂）在印度 HIV 感染者中的潜在效用提供关键的分析手段。本研究的目的是通过计算方法确定大量印度分离株的 HIV-1 嗜性，这些分离株既有来自原发性临床分离株，也有来自数据库衍生序列。

结果

总共 1045 例 HIV-1 亚型 C 的印度序列中，96.8%为 R5 嗜性。使用 C-PSSM 矩阵对 15 例原发性临床分离株进行辅助受体预测，发现了两株 X4 嗜性株。R5 嗜性 HIV-1 亚型 C 的 V3 序列比 X4 嗜性株更保守。X4 嗜性株来自于 HIV 诊断后时间明显更长（96.5 个月）的患者，而 R5 嗜性株则来自于诊断后时间较短（20.5 个月）的患者。